Stereotaxis - STXS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.50
  • Forecasted Upside: 148.62%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.81
▼ -0.01 (-0.55%)

This chart shows the closing price for STXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stereotaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STXS

Analyst Price Target is $4.50
▲ +148.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Stereotaxis in the last 3 months. The average price target is $4.50, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 148.62% upside from the last price of $1.81.

This chart shows the closing price for STXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Stereotaxis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/5/2024Lake Street CapitalBoost TargetBuy ➝ Buy$3.00 ➝ $4.00
3/5/2024Roth MkmReiterated RatingBuy ➝ Buy$5.00
1/10/2024Roth MkmInitiated CoverageBuy$5.00
3/6/2023Piper SandlerLower TargetOverweight$6.00 ➝ $5.00
3/6/2023Lake Street CapitalLower TargetBuy$5.00 ➝ $4.00
3/6/2023B. RileyLower TargetBuy$6.00 ➝ $5.50
11/11/2022CowenLower TargetOutperform$7.00 ➝ $5.00
8/9/2022Piper SandlerLower Target$8.00 ➝ $6.00
7/12/2022AegisInitiated CoverageBuy$6.00
6/23/2022B. RileyInitiated CoverageBuy$6.00
1/5/2022Craig HallumInitiated CoverageBuy$11.00
1/5/2022Loop CapitalInitiated CoverageBuy$13.00
7/1/2021Piper SandlerReiterated RatingOverweight$9.00 ➝ $11.00
6/25/2021Lake Street CapitalBoost TargetBuy$9.00 ➝ $12.00
5/26/2021Piper SandlerInitiated CoverageOverweight$9.00
12/30/2020Northland SecuritiesReiterated RatingBuy$7.00
9/8/2020Northland SecuritiesInitiated CoverageOutperform$9.50
6/22/2020Lake Street CapitalBoost TargetBuy$5.00 ➝ $9.00
4/19/2020CowenInitiated CoverageOutperform$6.00
4/9/2020CowenInitiated CoverageOutperform$6.00
4/7/2020Lake Street CapitalInitiated CoverageBuy$5.00
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.38 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/25/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Stereotaxis logo
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Read More

Today's Range

Now: $1.81
Low: $1.80
High: $1.86

50 Day Range

MA: N/A

52 Week Range

Now: $1.81
Low: $1.33
High: $3.29

Volume

131,755 shs

Average Volume

302,141 shs

Market Capitalization

$149.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Stereotaxis?

The following equities research analysts have issued stock ratings on Stereotaxis in the last year: Lake Street Capital, and Roth Mkm.
View the latest analyst ratings for STXS.

What is the current price target for Stereotaxis?

2 Wall Street analysts have set twelve-month price targets for Stereotaxis in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 148.6%. Roth Mkm has the highest price target set, predicting STXS will reach $5.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $4.00 for Stereotaxis in the next year.
View the latest price targets for STXS.

What is the current consensus analyst rating for Stereotaxis?

Stereotaxis currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STXS will outperform the market and that investors should add to their positions of Stereotaxis.
View the latest ratings for STXS.

What other companies compete with Stereotaxis?

Other companies that are similar to Stereotaxis include AxoGen, Zynex, Semler Scientific, Edap Tms and Outset Medical. Learn More about companies similar to Stereotaxis.

How do I contact Stereotaxis' investor relations team?

Stereotaxis' physical mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The company's listed phone number is (314) 678-6100 and its investor relations email address is [email protected]. The official website for Stereotaxis is www.stereotaxis.com. Learn More about contacing Stereotaxis investor relations.